Total Voting Rights

RNS Number : 9555J

Oxford Biomedica PLC

03 July 2017

 

Oxford BioMedica

Total Voting Rights

Oxford, UK - 3 July 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 30 June 2017 consisted of   3,088,726,215 ordinary shares of 1 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is       3,088,726,215.

The above figure (3,088,726,215) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

TVREADXDEFNXEFF